YOICHI HAMAI

Last Updated :2025/06/04

Affiliations, Positions
Hiroshima University Hospital, Associate Professor or Lecturer
E-mail
yyhamaihiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 1997/05/16, 1998/03/30, Hiroshima University, Medical Hospital, Clinical Resident
  • 1998/04/01, 2000/03/31, Hiroshima City Hospital
  • 2000/04/01, 2002/03/31, National Hospital Organization Shikoku Cancer Center
  • 2004/04/01, 2005/09/30, Hiroshima University Hospital, Clinical Fellow
  • 2005/10/01, 2007/03/31, Hiroshima University Hospital, Research Associate
  • 2007/04/01, 2012/12/31, Hiroshima University, Assistant Professor
  • 2013/01/01, 2016/03/31, Hiroshima University, Research Institute for Radiation Biology and Medicine, Research Center for Radiation Casualty Medicine, Assistant Professor
  • 2016/04/01, Hiroshima University Hospital, Lecturer

Educational Backgrounds

  • Hiroshima University, Japan, 2002/04, 2005/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical surgery;Digestive surgery

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2025, Undergraduate Education, Intensive, Practice of Medicine II
  4. 2025, Undergraduate Education, First Semester, Surgery I

Research Activities

Academic Papers

  1. Successful management of multiple esophagorespiratory fistulas using two types of stent: Report of a case, SURGERY TODAY, 41(4), 560-562, 201104
    Link to Paper Search Results by DOI
  2. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, SURGERY TODAY, 42(4), 342-350, 201204
    Link to Paper Search Results by DOI
  3. Airway Stenting for Malignant Respiratory Complications in Esophageal Cancer, ANTICANCER RESEARCH, 32(5), 1785-1790, 201205
    Link to Paper Search Results by DOI
  4. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6), 1499-1505, 201206
    Link to Paper Search Results by DOI
  5. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case, SURGERY TODAY, 42(11), 1088-1090, 201211
    Link to Paper Search Results by DOI
  6. Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report, BMC GASTROENTEROLOGY, 12, 20120731
    Link to Paper Search Results by DOI
  7. Airway Stenting for Tracheal Obstruction Due to Lymph Node Metastasis of Hepatocellular Carcinoma, ANTICANCER RESEARCH, 33(4), 1761-1764, 201304
    Link to Paper Search Results by DOI
  8. Involvement of ribonucleotide reductase-M1 in 5-fluorouracil-induced DNA damage in esophageal cancer cell lines, INTERNATIONAL JOURNAL OF ONCOLOGY, 42(6), 1951-1960, 201306
    Link to Paper Search Results by DOI
  9. Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion, ANTICANCER RESEARCH, 33(8), 3495-3502, 201308
    Link to Paper Search Results by DOI
  10. Esophageal Bypass Operation Prior to Definitive Chemoradiotherapy in Advanced Esophageal Cancer With Tracheobronchial Invasion, ANNALS OF THORACIC SURGERY, 97(1), 290-295, 201401
    Link to Paper Search Results by DOI
  11. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition, CANCER SCIENCE, 104(12), 1593-1599, 201312
    Link to Paper Search Results by DOI
  12. Melanoma-associated antigen-A1 expression predicts resistance to decetaxel and paclitaxel in advanced and recurrent gastric cancer, Oncol Rep, 18, 329-336, 20070101
  13. Melanoma-associated antigen-A1 expression predicts resistance to decetaxel and paclitaxel in advanced and recurrent gastric cancer., Oncol Rep, 18(2), 329-336, 20070601
  14. Emergency escape surgery for a gastro-bronchial fistula with respiratory failure that developed after esophagectomy, Surgery Today, 45(3), 369-373, 201503
    Link to Paper Search Results by DOI
  15. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer, DISEASES OF THE ESOPHAGUS, 28(4), 358-364, 2015
    Link to Paper Search Results by DOI
  16. Lung Abscess Presenting as Tension Pyopneumothorax in a Gastrointestinal Cancer Patient, ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 20, 478-481, 2014
    Link to Paper Search Results by DOI
  17. Advanced esophageal cancer with situs inversus totalis successfully treated with chemoradiotherapy followed by esophagectomy: case report, Hiroshima J Med Sci, 60(1), 21-4, 20110601
  18. Skin tube reconstruction for esophageal defect due to postoperative complication, Ann Thorac Surg, 87(5), 1605-7, 20090501
  19. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines, Oncol Rep, 17(1), 161-7, 20070101
  20. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer, Anticancer Research, 27(4C), 2597-603, 20070701
  21. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer, ANTICANCER RESEARCH, 26(1A), 49-54, 2006
    Link to Paper Search Results by DOI
  22. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: Possible application for compensatory anti-inflammatory response syndrome, ONCOLOGY REPORTS, 15(4), 895-901, 200604
    Link to Paper Search Results by DOI
  23. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines, ONCOLOGY REPORTS, 17(1), 161-167, 200701
    Link to Paper Search Results by DOI
  24. Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer, ONCOLOGY REPORTS, 18(2), 329-336, 200708
    Link to Paper Search Results by DOI
  25. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer, ANTICANCER RESEARCH, 27(4C), 2597-2603, 2007
    Link to Paper Search Results by DOI
  26. Laparoscopic Thoracic Duct Clipping for Persistent Chylothorax After Extrapleural Pneumonectomy, ANNALS OF THORACIC SURGERY, 93(5), E131-E132, 201205
    Link to Paper Search Results by DOI
  27. Hemoglobin Level Influences Tumor Response and Survival After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma, WORLD JOURNAL OF SURGERY, 38(8), 2046-2051, 201408
    Link to Paper Search Results by DOI
  28. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer, ANNALS OF THORACIC SURGERY, 99(6), 1887-1893, 201506
    Link to Paper Search Results by DOI
  29. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma, 94(8), 692-698, 20030831
  30. Clinical Significance of FDG-PET to Predict Pathologic Tumor Invasion and Lymph Node Metastasis of Superficial Esophageal Squamous Cell Carcinoma, ANNALS OF SURGICAL ONCOLOGY, 23(12), 4086-4092, 201611
    Link to Paper Search Results by DOI
  31. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma, ANNALS OF THORACIC SURGERY, 102(4), 1132-1140, 201610
    Link to Paper Search Results by DOI
  32. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study, DISEASES OF THE ESOPHAGUS, 29(8), 1115-1120, 2016
    Link to Paper Search Results by DOI
  33. Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer, WORLD JOURNAL OF SURGERY, 41(6), 1558-1565, 201706
    Link to Paper Search Results by DOI
  34. Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer., World J Surg, 41(6), 1558-1565
  35. Surgical Resection of Thoracic Esophageal Cancer with Interstitial Lung Disease: A Case Report., Hiroshima J Med Sci., 65(1), 19-23, 2017
  36. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 37(10), 5639-5646, 201710
    Link to Paper Search Results by DOI
  37. Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma, ANNALS OF THORACIC SURGERY, 104(6), 1858-1864, 201712
    Link to Paper Search Results by DOI
  38. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery, WORLD JOURNAL OF SURGERY, 42(5), 1496-1505, 201805
    Link to Paper Search Results by DOI
  39. Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma, WORLD JOURNAL OF SURGERY, 42(7), 2190-2198, 201807
    Link to Paper Search Results by DOI
  40. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy, SURGERY, 164(1), 40-48, 201807
    Link to Paper Search Results by DOI
  41. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma., J Radiat Res.
  42. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus.
  43. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus, ANTICANCER RESEARCH, 38(9), 5239-5245, 201809
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Prediction of tumor response and survival by using 18F-fluorodeoxyglucose positron emission tomography in trimodality therapy for esophageal squamous cell carcinoma, Hamai, Y, Hihara, J., Furukawa, T., Yamakita, I., Kurokawa, T., Okada, M, 18Th European Cancer Congress, 2015, Without Invitation, Japanese
  2. Prediction of tumor response and survival with use of FDG-PET after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma, 2015, Hamai, Y, The 115th Annual Congress of Japan Surgical Society, Without Invitation, Japanese
  3. Prediction of lymph node metastasis and survival by PET in trimodal therapy for esophageal cancer, Hamai, Y, Hihara, J., Furukawa, T., Yamakita, I., Okada, M, 70th General Meeting of the Japanese Society of Gastroenterological Surgery, 2015, Without Invitation, Japanese
  4. The effects of neoadjuvant chemoradiotherapy on TNM staging and its prognostic significance in esophageal squamous cell carcinoma, Hamai, Y, Hihara, J., Furukawa, T., Yamakita, I., Okada, M, The 69th Annual Meeting of the Japan Esophageal Society, 2015, Without Invitation, Japanese

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI, 2012, 2014
    Permalink
  2. KAKENHI, The development of novel molecular target drug : Identification of RNA aptamer targeting human epidermal growth factor by SELEX, 2010, 2011
    Permalink
  3. KAKENHI, 2015, 2017
    Permalink